drugset / Trial / NCT02482935

A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without Food

NCT02482935

Phase 1 Completed 30 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to evaluate the amount of abemaciclib that reaches the blood stream and how long the body takes to get rid of it when given with and without food. In addition, the safety and tolerability of the study drug will be evaluated. Information about any side effects that may occur will also be collected. The study will last about 43 days for each participant, not including screening.

Timeline

Start
2015-06
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Abemaciclib Small molecule Oral

Indications

No indication recorded.